TriSalus Life Sciences Inc

Research TriSalus Life Sciences Inc (TLSI) on Bullrun: market cap USD 309.19M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 309.19M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 45.15M-USD 39.23M-USD 18.93M84.6%-1.84USD 20.44MUSD 33.05M-USD 33.86M
FY2024USD 29.43M-USD 30.05M-USD 41.19M86.1%-1.31USD 8.53MUSD 22.08M-USD 25.89M
FY2023USD 18.51M-USD 59.36M-USD 51.17M85.9%-6.77USD 11.78MUSD 0-USD 27.07M
FY2022USD 12.40M-USD 47.19M-USD 32.97M81.8%-161.55USD 9.41Mn/a-USD 177.13M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 309.19Mn/an/an/a
20252025-12-31USD 348.98Mn/an/an/a
20242024-12-31USD 156.71Mn/an/an/a
20232023-12-29USD 223.19Mn/an/an/a
20222022-09-29n/a31.1n/an/a
20212021-12-31n/a65.9n/an/a

About TriSalus Life Sciences Inc

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is TriSalus Life Sciences Inc's market cap?

TriSalus Life Sciences Inc's market capitalization is USD 309.19M.

What does TriSalus Life Sciences Inc do?

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.